You are here: HomeSearch
Keywords you search:
-
Description Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine (MCV4) developed by Tianjin Cansino Biotechnology has been approved for ...
-
Description Meningococcal Group AC Bivalent Conjugate Vaccine, Freeze Dried (MCV2) developed by Tianjin Cansino Biotechnology has been approved for clinical trial by China Food ...
-
Description Ridding the World of Tuberculosis
-
Description August 2 nd 2016, Tianjin CanSino submits the Clinical trial applicationfor the component DTP combo vaccine andsuccessfullyreceives the “drug application registration”. This product is the first DTP vaccine ...
-
Description March 20, 2018 – Montreal, QC - In response to the Ebola outbreak that claimed more than 10,000 lives in West Africa four years ago, Canada and China worked on a new Ebola vaccine.
-
Description Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of China’s CanSino Biologics in collaboration focused on herpes zoster.
-
Description Oct 31, 2018, CanSino Biologics Inc. announced that the company’s innovative vaccine candidate “Protein-based Pneumococcal Vaccine” (PBPV) obtained approval for clinical trials from the Center for Drug Evaluation (CDE) of National Medical Product Agency (NMPA) in China.
-
Description On Jan. 2, 2019, CanSino Biologics Inc. announces that the company submitted the clinical trial application of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(with CRM197 and TT carrier proteins) to Chinese national regulatory authorities NMPA on Dec 29, 2018.
-
Description On January 14, 2019. CanSino Biologics Inc., (CanSinoBIO) a China-based vaccine company focusing on the development and manufacturing of preventive and therapeutic vaccines announced that the company signed a supply agreement with VaxYnethic (Siena, Italy) for the development and production of conjugated vaccines for human use.
-
Description January 31, 2019, , CanSino Biologics Inc. (CanSinoBIO) announced that the company submitted a NDA/BLA application for a bivalent meningococcal conjugate vaccine to Center of Drug Evaluation (CDE), a division of National Medicine Product Administration (NMPA) of China.